Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A2 | P11168 | 2/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 13/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.43 |
| ▸ | TOP2A | P11388 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3499390 | 0.80 | SLC2A2 (0.58) | SLC2A2SLC2A1 | |
| SCHEMBL9923914 | 0.78 | KDM4E (0.51) | ALDH1A1 | |
| SCHEMBL9893259 | 0.75 | USP7 (0.43) | SLC2A1ALDH1A1 | |
| SCHEMBL3498373 | 0.74 | CDH1 (0.50) | SLC2A2SLC2A1ALDH1A1 | |
| SCHEMBL312556 | 0.73 | EPHB3 (0.56) | EGLN1 | |
| SCHEMBL9924041 | 0.72 | ALDH1A1 (0.50) | ALDH1A1 | |
| SCHEMBL9924007 | 0.71 | PTGS1 (0.66) | ALDH1A1 | |
| SCHEMBL3498537 | 0.71 | EGLN1 (0.67) | EGLN1ALDH1A1ALDH1A3 | |
| Hydrochloric Acid SCHEMBL28455052 | 0.70 | PTGS1 (0.64) | ALDH1A1 | |
| SCHEMBL16463073 | 0.70 | GABRA2 (0.49) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | SLC2A2 1403/4885SLC2A1 1193/4885EGLN1 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.